Conditions: Psoriasis
Keywords: Moderate to Severe Chronic plaque type psoriasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events. Although systemic therapy with immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic inflammation and endothelial function are unknown.

In this study we want to assess the cardiovascular risks factors, endothelial dysfunction and inflammatory markers before and after treatment of moderate to severe psoriasis with an FDA-approved biologic agent, adalimumab (Humira).

Detailed description:

Arms:
arm 1: Adalimumab 40 MG/0.8 ML Subcutaneous Solution \[HUMIRA\] Dose administered every other week for 6 months

Interventions: intervention 1: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Intervention descriptions: intervention 1: 40mg subcutaneously, every other week for 6 months

Protocol document: